https://www.ascopost.com/issues/july-25-2021/benefits-of-adjuvant-pembrolizumab-in-melanoma-reinforced-by-eortc-1325keynote-054-updates/
https://ascopost.com/issues/july-25-2021/benefits-of-adjuvant-pembrolizumab-in-melanoma-reinforced-by-eortc-1325keynote-054-updates/
https://www.ascopost.com/news/july-2021/addition-of-ipilimumab-to-nivolumab-in-previously-treated-immunotherapy-naive-stage-iv-squamous-nsclc/
https://ascopost.com/news/july-2021/addition-of-ipilimumab-to-nivolumab-in-previously-treated-immunotherapy-naive-stage-iv-squamous-nsclc/
https://www.ascopost.com/news/july-2021/interleukin-2-pathway-agonist-bempegaldesleukin-plus-nivolumab-in-the-first-line-treatment-of-metastatic-melanoma/
https://ascopost.com/news/july-2021/interleukin-2-pathway-agonist-bempegaldesleukin-plus-nivolumab-in-the-first-line-treatment-of-metastatic-melanoma/
https://www.ascopost.com/issues/july-10-2021/epov-jason-luke/
https://ascopost.com/issues/july-10-2021/epov-jason-luke/
https://www.ascopost.com/issues/july-10-2021/nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer/
https://ascopost.com/issues/july-10-2021/nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer/
https://www.ascopost.com/issues/july-10-2021/a-shift-in-the-treatment-of-advanced-melanoma/
https://ascopost.com/issues/july-10-2021/a-shift-in-the-treatment-of-advanced-melanoma/
https://www.ascopost.com/issues/july-10-2021/responses-to-pembrolizumab-and-ipilimumab-after-anti-pd-1l1-failure-in-advanced-melanoma/
https://ascopost.com/issues/july-10-2021/responses-to-pembrolizumab-and-ipilimumab-after-anti-pd-1l1-failure-in-advanced-melanoma/
https://www.ascopost.com/issues/june-25-2021/epov-rui-hua-xu/
https://ascopost.com/issues/june-25-2021/epov-rui-hua-xu/
https://www.ascopost.com/issues/june-25-2021/checkmate-648-first-line-nivolumab-regimens-improve-survival-in-esophageal-squamous-cell-carcinoma/
https://ascopost.com/issues/june-25-2021/checkmate-648-first-line-nivolumab-regimens-improve-survival-in-esophageal-squamous-cell-carcinoma/
https://www.ascopost.com/issues/june-25-2021/epov-rana-r-mckay/
https://ascopost.com/issues/june-25-2021/epov-rana-r-mckay/
https://www.ascopost.com/videos/2021-asco-annual-meeting/martin-reck-on-nsclc-nivolumab-ipilimumab-and-chemotherapy-for-advanced-disease/
https://ascopost.com/videos/2021-asco-annual-meeting/martin-reck-on-nsclc-nivolumab-ipilimumab-and-chemotherapy-for-advanced-disease/
https://www.ascopost.com/videos/2021-asco-annual-meeting/matt-galsky-on-bladder-cancer-neoadjuvant-therapy-with-gemcitabine-cisplatin-and-nivolumab/
https://ascopost.com/videos/2021-asco-annual-meeting/matt-galsky-on-bladder-cancer-neoadjuvant-therapy-with-gemcitabine-cisplatin-and-nivolumab/
https://www.ascopost.com/news/june-2021/addition-of-first-line-nivolumab-to-chemotherapy-in-advanced-gastric-cancers-checkmate-649/
https://ascopost.com/news/june-2021/addition-of-first-line-nivolumab-to-chemotherapy-in-advanced-gastric-cancers-checkmate-649/
https://www.ascopost.com/news/june-2021/epov-anthony-tc-chan/
https://ascopost.com/news/june-2021/epov-anthony-tc-chan/
https://www.ascopost.com/issues/june-25-2021/epov-mansoor-raza-mirza/
https://ascopost.com/issues/june-25-2021/epov-mansoor-raza-mirza/
https://www.ascopost.com/issues/june-10-2021/dual-immune-checkpoint-blockade-with-nivolumab-and-ipilimumab-for-treatment-of-malignant-pleural-mesothelioma/
https://ascopost.com/issues/june-10-2021/dual-immune-checkpoint-blockade-with-nivolumab-and-ipilimumab-for-treatment-of-malignant-pleural-mesothelioma/
https://www.ascopost.com/issues/june-10-2021/nivolumabipilimumab-improves-overall-survival-vs-chemotherapy-in-first-line-treatment-for-unresectable-malignant-pleural-mesothelioma/
https://ascopost.com/issues/june-10-2021/nivolumabipilimumab-improves-overall-survival-vs-chemotherapy-in-first-line-treatment-for-unresectable-malignant-pleural-mesothelioma/
https://www.ascopost.com/issues/june-10-2021/disease-free-survival-benefit-with-adjuvant-immunotherapy-in-resectable-esophageal-cancer-practice-changing-for-all-patients/
https://ascopost.com/issues/june-10-2021/disease-free-survival-benefit-with-adjuvant-immunotherapy-in-resectable-esophageal-cancer-practice-changing-for-all-patients/
https://www.ascopost.com/issues/june-10-2021/adjuvant-nivolumab-improves-disease-free-survival-vs-placebo-in-resected-esophageal-or-gastroesophageal-junction-cancer-after-neoadjuvant-chemoradiotherapy/
https://ascopost.com/issues/june-10-2021/adjuvant-nivolumab-improves-disease-free-survival-vs-placebo-in-resected-esophageal-or-gastroesophageal-junction-cancer-after-neoadjuvant-chemoradiotherapy/
https://www.ascopost.com/issues/june-10-2021/cabozantinib-with-nivolumab-for-metastatic-renal-cell-carcinoma/
https://ascopost.com/issues/june-10-2021/cabozantinib-with-nivolumab-for-metastatic-renal-cell-carcinoma/
https://www.ascopost.com/news/june-2021/checkmate-274-adjuvant-nivolumab-in-high-risk-muscle-invasive-urothelial-carcinoma/
https://ascopost.com/news/june-2021/checkmate-274-adjuvant-nivolumab-in-high-risk-muscle-invasive-urothelial-carcinoma/
https://www.ascopost.com/issues/june-10-2021/omid-hamid-discusses-relativity-047/
https://ascopost.com/issues/june-10-2021/omid-hamid-discusses-relativity-047/
https://www.ascopost.com/issues/june-10-2021/targeting-lag-3-and-pd-1-with-relatlimab-and-nivolumab-a-new-option-under-study-in-advanced-melanoma/
https://ascopost.com/issues/june-10-2021/targeting-lag-3-and-pd-1-with-relatlimab-and-nivolumab-a-new-option-under-study-in-advanced-melanoma/
https://www.ascopost.com/news/june-2021/no-survival-difference-for-front-line-combination-regimens-in-intermediate-and-poor-risk-clear-cell-rcc/
https://ascopost.com/news/june-2021/no-survival-difference-for-front-line-combination-regimens-in-intermediate-and-poor-risk-clear-cell-rcc/
https://www.ascopost.com/news/june-2021/nivolumab-plus-chemotherapy-and-nivolumab-plus-ipilimumab-as-first-line-treatment-for-patients-with-advanced-esophageal-cancer/
https://ascopost.com/news/june-2021/nivolumab-plus-chemotherapy-and-nivolumab-plus-ipilimumab-as-first-line-treatment-for-patients-with-advanced-esophageal-cancer/
https://www.ascopost.com/news/june-2021/extended-follow-up-of-nivolumabipilimumab-for-metastatic-melanoma/
https://ascopost.com/news/june-2021/extended-follow-up-of-nivolumabipilimumab-for-metastatic-melanoma/
https://www.ascopost.com/videos/2021-asco-annual-meeting/ian-chau-on-esophageal-squamous-cell-carcinoma-nivolumab-ipilimumab-and-chemotherapy/
https://ascopost.com/videos/2021-asco-annual-meeting/ian-chau-on-esophageal-squamous-cell-carcinoma-nivolumab-ipilimumab-and-chemotherapy/
https://www.ascopost.com/issues/june-3-2021-narratives-special-issue/new-fda-approved-oncology-drugs-and-label-updates-between-may-8-2020-and-may-8-2021/
https://ascopost.com/issues/june-3-2021-narratives-special-issue/new-fda-approved-oncology-drugs-and-label-updates-between-may-8-2020-and-may-8-2021/
https://www.ascopost.com/videos/2021-asco-annual-meeting/evan-lipson-on-melanoma-relatlimab-and-nivolumab-in-first-line-treatment-of-advanced-disease/
https://ascopost.com/videos/2021-asco-annual-meeting/evan-lipson-on-melanoma-relatlimab-and-nivolumab-in-first-line-treatment-of-advanced-disease/
https://www.ascopost.com/issues/may-25-2021/first-line-nivolumab-plus-cabozantinib-improves-progression-free-and-overall-survival-vs-sunitinib-in-advanced-renal-cell-carcinoma/
https://ascopost.com/issues/may-25-2021/first-line-nivolumab-plus-cabozantinib-improves-progression-free-and-overall-survival-vs-sunitinib-in-advanced-renal-cell-carcinoma/
https://www.ascopost.com/issues/may-25-2021/empower-lung-1-trial-new-options-no-new-answers/
https://ascopost.com/issues/may-25-2021/empower-lung-1-trial-new-options-no-new-answers/
https://www.ascopost.com/issues/may-25-2021/fda-odac-meeting-focuses-on-dangling-accelerated-approvals-of-anti-pd-1pd-l1-antibodies/
https://ascopost.com/issues/may-25-2021/fda-odac-meeting-focuses-on-dangling-accelerated-approvals-of-anti-pd-1pd-l1-antibodies/
https://www.ascopost.com/issues/may-25-2021/pembrolizumab-as-long-term-treatment-option-in-relapsed-or-refractory-classic-hodgkin-lymphoma/
https://ascopost.com/issues/may-25-2021/pembrolizumab-as-long-term-treatment-option-in-relapsed-or-refractory-classic-hodgkin-lymphoma/
https://www.ascopost.com/issues/may-25-2021/nccn-clinical-practice-guidelines-in-oncology-2021-updates/
https://ascopost.com/issues/may-25-2021/nccn-clinical-practice-guidelines-in-oncology-2021-updates/
https://www.ascopost.com/news/may-2021/ipilimumab-plus-anti-pd-1-therapy-vs-ipilimumab-alone-for-patients-with-advanced-melanoma-resistant-to-anti-pd-1l1-monotherapy/
https://ascopost.com/news/may-2021/ipilimumab-plus-anti-pd-1-therapy-vs-ipilimumab-alone-for-patients-with-advanced-melanoma-resistant-to-anti-pd-1l1-monotherapy/
https://www.ascopost.com/issues/june-10-2021/fda-approves-nivolumab-for-resected-esophageal-or-gastroesophageal-junction-cancer/
https://ascopost.com/issues/june-10-2021/fda-approves-nivolumab-for-resected-esophageal-or-gastroesophageal-junction-cancer/
https://www.ascopost.com/news/may-2021/first-line-nivolumabrelatlimab-vs-nivolumab-alone-for-advanced-melanoma/
https://ascopost.com/news/may-2021/first-line-nivolumabrelatlimab-vs-nivolumab-alone-for-advanced-melanoma/
https://www.ascopost.com/issues/may-10-2021/adjuvant-immunotherapy-of-benefit-to-patients-with-stage-iibc-melanoma/
https://ascopost.com/issues/may-10-2021/adjuvant-immunotherapy-of-benefit-to-patients-with-stage-iibc-melanoma/
https://www.ascopost.com/issues/may-10-2021/epov-alexander-eggermont/
https://ascopost.com/issues/may-10-2021/epov-alexander-eggermont/
https://www.ascopost.com/issues/may-10-2021/comparing-nivolumab-plus-ipilimumab-vs-nivolumab-alone-in-resected-stage-iii-to-iv-melanoma/
https://ascopost.com/issues/may-10-2021/comparing-nivolumab-plus-ipilimumab-vs-nivolumab-alone-in-resected-stage-iii-to-iv-melanoma/
https://www.ascopost.com/issues/may-10-2021/fda-approves-nivolumab-in-combination-with-chemotherapy-for-metastatic-gastric-cancer-and-esophageal-adenocarcinoma/
https://ascopost.com/issues/may-10-2021/fda-approves-nivolumab-in-combination-with-chemotherapy-for-metastatic-gastric-cancer-and-esophageal-adenocarcinoma/
https://www.ascopost.com/issues/may-10-2021/cannabis/
https://ascopost.com/issues/may-10-2021/cannabis/
https://www.ascopost.com/issues/may-10-2021/epov-jhanelle-gray/
https://ascopost.com/issues/may-10-2021/epov-jhanelle-gray/
https://www.ascopost.com/issues/may-10-2021/squamous-cell-carcinoma-of-the-head-and-neck-current-status-and-future-directions-1/
https://ascopost.com/issues/may-10-2021/squamous-cell-carcinoma-of-the-head-and-neck-current-status-and-future-directions-1/
https://www.ascopost.com/issues/may-10-2021/neoadjuvant-nivolumab-plus-chemotherapy-boosts-pathologic-complete-response-in-resectable-nsclc/
https://ascopost.com/issues/may-10-2021/neoadjuvant-nivolumab-plus-chemotherapy-boosts-pathologic-complete-response-in-resectable-nsclc/
https://www.ascopost.com/news/may-2021/fda-pipeline-priority-reviews-of-treatments-for-bladder-and-lung-cancers/
https://ascopost.com/news/may-2021/fda-pipeline-priority-reviews-of-treatments-for-bladder-and-lung-cancers/
https://www.ascopost.com/news/april-2021/more-from-the-fda-odac-votes-on-agents-for-pretreated-hepatocellular-carcinoma-and-gastric-cancer/
https://ascopost.com/news/april-2021/more-from-the-fda-odac-votes-on-agents-for-pretreated-hepatocellular-carcinoma-and-gastric-cancer/
https://www.ascopost.com/issues/april-25-2021/transmission-of-cancer-to-infants-from-mothers-with-cervical-cancer-during-vaginal-delivery/
https://ascopost.com/issues/april-25-2021/transmission-of-cancer-to-infants-from-mothers-with-cervical-cancer-during-vaginal-delivery/
https://www.ascopost.com/news/april-2021/dangling-accelerated-approvals-of-anti-pd-1pd-l1-antibodies-to-be-discussed-at-fda-oncologic-drugs-advisory-committee-meeting/
https://ascopost.com/news/april-2021/dangling-accelerated-approvals-of-anti-pd-1pd-l1-antibodies-to-be-discussed-at-fda-oncologic-drugs-advisory-committee-meeting/
https://www.ascopost.com/issues/april-25-2021/nivolumabipilimumab-plus-two-cycles-of-histology-based-chemotherapy-another-option-in-first-line-metastatic-nsclc/
https://ascopost.com/issues/april-25-2021/nivolumabipilimumab-plus-two-cycles-of-histology-based-chemotherapy-another-option-in-first-line-metastatic-nsclc/